Pay in 4 interest-free payments of $5.48 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
The double-blind STRIDE trial, conducted at 112 outpatient clinics in North America, Asia and Europe from October 2020 to July 2024, randomized 792 participants (median age 68 years, 25% women, 68% White) with T2D and PAD with intermittent claudication (Fontaine stage IIa) as well as an ankle-brachial index of 0.90 (mean 0.75) or toe-brachial index 0.70 (mean 0.48) to either once-weekly doses of subcutaneous semaglutide (n=396) or placebo (n=396) for 52 weeks
Keep locked and away from children
Retatrutide is still investigational, has not been approved by regulators and cannot legally be prescribed or supplied as a weight loss treatment
This type of lactose intolerance is rare and develops at birth
We adjust treatment plans based on your response and help troubleshoot challenges like exercise modifications during dose changes
